Absci Corporation (ABSI)Healthcare | Biotechnology | Vancouver, United States | NasdaqGS
3.58 USD
+0.35
(10.836%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 3.55 -0.03 (-0.030%) ⇩ (April 17, 2026, 7:51 p.m. EDT) Short-term: ★☆☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 1:17 p.m. EDT
Absci Corporation (ABSI) is facing a short-term bearish bias in the options market, with higher put activity and elevated IV indicating potential for near-term downside. While there are some bullish calls at the ATM strike, the overall sentiment leans towards caution, suggesting a short-term sell or short put strategy. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.076944 |
| AutoETS | 0.077145 |
| AutoARIMA | 0.077146 |
| MSTL | 0.077715 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.341 |
| Excess Kurtosis | -0.73 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.799 |
| Revenue per Share | 0.02 |
| Market Cap | 547,816,128 |
| Forward P/E | -5.71 |
| Beta | 2.01 |
| Previous Name | Absci, CORP |
| Website | https://www.absci.com |
As of April 18, 2026, 1:17 p.m. EDT: Speculators are showing mixed sentiment with a focus on downside protection. Puts are showing higher implied volatility (IV) and open interest (OI), particularly around strikes below the current price, indicating a bearish bias. Calls are less active, with significant OI at the ATM strike of 4.0, suggesting some bullish positioning, but not enough to outweigh the bearish put activity. Overall, the options market suggests a cautious outlook with a leaning towards short-term downside.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.16612375 |
| Address1 | 18,105 SE Mill Plain Boulevard |
| All Time High | 31.53 |
| All Time Low | 1.111 |
| Ask | 3.61 |
| Ask Size | 16 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.4 - Strong Buy |
| Average Daily Volume10 Day | 3,710,550 |
| Average Daily Volume3 Month | 3,593,835 |
| Average Volume | 3,593,835 |
| Average Volume10Days | 3,710,550 |
| Beta | 2.013 |
| Bid | 3.56 |
| Bid Size | 60 |
| Board Risk | 8 |
| Book Value | 1.25 |
| City | Vancouver |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.58 |
| Current Ratio | 6.57 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 3.735 |
| Day Low | 3.33 |
| Debt To Equity | 2.799 |
| Display Name | Absci |
| Earnings Call Timestamp End | 1,774,384,200 |
| Earnings Call Timestamp Start | 1,774,384,200 |
| Earnings Timestamp | 1,774,382,400 |
| Earnings Timestamp End | 1,778,875,200 |
| Earnings Timestamp Start | 1,778,875,200 |
| Ebitda | -112,976,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.619 |
| Enterprise To Revenue | 146.009 |
| Enterprise Value | 408,826,112 |
| Eps Current Year | -0.80097 |
| Eps Forward | -0.62647 |
| Eps Trailing Twelve Months | -0.84 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.7945 |
| Fifty Day Average Change | 0.7854998 |
| Fifty Day Average Change Percent | 0.2810878 |
| Fifty Two Week Change Percent | 16.612375 |
| Fifty Two Week High | 5.228 |
| Fifty Two Week High Change | -1.6480002 |
| Fifty Two Week High Change Percent | -0.31522575 |
| Fifty Two Week Low | 2.24 |
| Fifty Two Week Low Change | 1.3399999 |
| Fifty Two Week Low Change Percent | 0.59821427 |
| Fifty Two Week Range | 2.24 - 5.228 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,626,960,600,000 |
| Float Shares | 143,279,929 |
| Forward Eps | -0.62647 |
| Forward P E | -5.714559 |
| Free Cashflow | -37,195,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 140 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -77,918,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13352999 |
| Held Percent Institutions | 0.76088995 |
| Implied Shares Outstanding | 153,021,263 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-22 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington. |
| Long Name | Absci Corporation |
| Market | us_market |
| Market Cap | 547,816,128 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_266013918 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-19 |
| Net Income To Common | -115,183,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 549,346,334 |
| Number Of Analyst Opinions | 7 |
| Open | 3.33 |
| Operating Cashflow | -92,925,000 |
| Operating Margins | -54.526154 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 360 949 1041 |
| Post Market Change | -0.030099869 |
| Post Market Change Percent | -0.84077847 |
| Post Market Price | 3.5499 |
| Post Market Time | 1,776,469,877 |
| Prev Name | Absci, CORP |
| Previous Close | 3.23 |
| Price Eps Current Year | -4.4695807 |
| Price Hint | 4 |
| Price To Book | 2.8639998 |
| Price To Sales Trailing12 Months | 195.64862 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.338 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.44444 |
| Region | US |
| Regular Market Change | 0.35 |
| Regular Market Change Percent | 10.8359 |
| Regular Market Day High | 3.735 |
| Regular Market Day Low | 3.33 |
| Regular Market Day Range | 3.33 - 3.735 |
| Regular Market Open | 3.33 |
| Regular Market Previous Close | 3.23 |
| Regular Market Price | 3.58 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 6,433,477 |
| Return On Assets | -0.36263 |
| Return On Equity | -0.62501 |
| Revenue Growth | -0.023 |
| Revenue Per Share | 0.02 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 153,021,263 |
| Shares Percent Shares Out | 0.2439 |
| Shares Short | 37,328,959 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 38,494,004 |
| Short Name | Absci Corporation |
| Short Percent Of Float | 0.2859 |
| Short Ratio | 8.69 |
| Source Interval | 15 |
| State | WA |
| Symbol | ABSI |
| Target High Price | 10.0 |
| Target Low Price | 4.2 |
| Target Mean Price | 8.02857 |
| Target Median Price | 9.0 |
| Total Cash | 144,292,000 |
| Total Cash Per Share | 0.943 |
| Total Debt | 5,302,000 |
| Total Revenue | 2,800,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.84 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.1064 |
| Two Hundred Day Average Change | 0.4735999 |
| Two Hundred Day Average Change Percent | 0.15245941 |
| Type Disp | Equity |
| Volume | 6,433,477 |
| Website | https://www.absci.com |
| Zip | 98,683 |